US 6,982,148 B2 | ||
Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis | ||
Paul B. Fisher, Scarsdale, N.Y. (US); and Zao-Zhong Su, New York, N.Y. (US) | ||
Assigned to The Trustees of Columbia University in the City of New York, New York, N.Y. (US) | ||
Filed on Jun. 20, 2002, as Appl. No. 10/177,811. | ||
Application 10/177811 is a continuation of application No. PCT/US00/34564, filed on Dec. 20, 2000. | ||
Claims priority of provisional application 60/173114, filed on Dec. 27, 1999. | ||
Prior Publication US 2003/0044828 A1, Mar. 06, 2003 | ||
Int. Cl. C12Q 1/68 (2006.01) |
U.S. Cl. 435—6 | 2 Claims |
1. A method for identifying a compound which inhibits angiogenesis in a tumor which comprises:
a) contacting a cancer cell with a compound to be tested, wherein the cancer cell normally expresses a PEG3 gene;
b) measuring PEG3 gene expression in the cancer cell;
c) determining whether PEG3 gene expression has been inhibited, wherein inhibition of PEG3 gene expression indicates the identification
of a compound which inhibits angiogenesis.
|